Accordingly, intravenous injection of high-dose (10 mg/kg) IgBD-TRAIL only showed mild tumor growth suppression in mice bearing LS174T or HT29 tumor grafts (Figure 1D), indicating that monotherapy of TRAIL proteins is hopeful but inefficient to combat CRC cells with both chemotherapeutic MDR and TRAIL resistance. Here, TNFSF10 is linked to neoplasm.